First-line dual PD-1/CTLA-4 blockade significantly improves PFS and response rates compared to PD-1 monotherapy in dMMR/MSI-H metastatic colorectal cancer, with manageable toxicity. #crcsm pubmed.ncbi.nlm.nih.gov/4083…

S1922 is a study for people with advanced small bowel #cancer. It tests 2 treatments that have been FDA-approved to treat other cancers. Learn more at awb://SWOG.org/S1922. Or call 1-800-4- CANCER. Ask about S1922. #crcsm #SmallIntestineCancer #RareCancers